Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Momelotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 20/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 10/20 | 1.00 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 16/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | OPA1 | O60313 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 1/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Momelotinib SCHEMBL22282523 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2237234 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2863022 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL29774318 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL17333087 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2863013 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL3619656 | 0.97 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL30051896 | 0.97 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL3619662 | 0.97 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| SCHEMBL2858799 | 0.94 | JAK2 (0.89) | JAK2JAK3JAK1HDAC1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3356 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137953-A1 | METHOD FOR TARGETED TREATING DERMATOSES | STRATA SKIN SCIENCES INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026102321-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | MARO BIO INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-12611408-B2 | Methods for treating nail brittleness, fragility, or pitting | CHEMISTRY RX (US) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | claimed |
| US-20260098088-A1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | DISC MEDICINE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| CN-114262344-A | Charged linkers and their use in conjugation reactions | 杭州多禧生物科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| WO-2022061001-A1 | METHODS FOR PATENT SELECTION AND TREATMENT OF CANCER | SPLASH PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022023490-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-3944859-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | Assistance Publique Hôpitaux de Paris (FR) | 2022-02-02 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |